Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 2/20 | 0.53 |
| ▸ | CHRM2 | P08172 | 13/20 | 0.49 |
| ▸ | CHRM4 | P08173 | 13/20 | 0.49 |
| ▸ | CHRM5 | P08912 | 13/20 | 0.49 |
| ▸ | CHRM1 | P11229 | 13/20 | 0.49 |
| ▸ | CHRM3 | P20309 | 13/20 | 0.49 |
| ▸ | NOS3 | P29474 | 1/20 | 0.45 |
| ▸ | NOS2 | P35228 | 1/20 | 0.45 |
| ▸ | PIM1 | P11309 | 2/20 | 0.41 |
| ▸ | PIM3 | Q86V86 | 2/20 | 0.41 |
| ▸ | FDFT1 | P37268 | 1/20 | 0.41 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4311598 | 0.83 | CHRM2 (0.54) | NOS1CHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL12253743 | 0.81 | NOS1 (0.56) | NOS1CHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL4814099 | 0.78 | FDFT1 (0.54) | NOS1CHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL1122492 | 0.76 | SLC6A4 (0.52) | NOS1CHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL12253750 | 0.76 | SLC6A4 (0.52) | NOS1CHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL24022684 | 0.74 | IMPDH2 (0.61) | PIM1PIM3PIM2 | |
| SCHEMBL18552149 | 0.74 | IMPDH2 (0.61) | PIM1PIM3PIM2 | |
| SCHEMBL18552198 | 0.74 | IMPDH2 (0.61) | PIM1PIM3PIM2 | |
| SCHEMBL12367627 | 0.73 | NOS1 (0.55) | NOS1CHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL2264789 | 0.73 | NOS1 (0.55) | NOS1CHRM2CHRM4CHRM5CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080132704-A1 | 3-Substituted quinuclidines and their use | PETERS DAN | 2008-06-05 | — | — | US | claimed |
| US-20050176756-A1 | 3-Substituted quinuclidines and their use | NEUROSEARCH A/S (DK) | 2005-08-11 | — | — | US | claimed |
| EP-1513839-A1 | 3-SUBSTITUTED QUINUCLIDINES AND THEIR USE | NEUROSEARCH A/S (DK) | 2005-03-16 | — | — | EP | claimed |
| WO-2003101987-A1 | 3-SUBSTITUTED QUINUCLIDINES AND THEIR USE | NEUROSEARCH A/S (DK) | 2003-12-11 | — | — | WO | claimed |
| US-20080132704-A1 | 3-Substituted quinuclidines and their use | PETERS DAN | 2008-06-05 | — | — | US | disclosed |
| US-7332507-B2 | 3-substituted quinuclidines and their use | NEUROSEARCH A/S (DK) | 2008-02-19 | — | — | US | disclosed |
| US-20050176756-A1 | 3-Substituted quinuclidines and their use | NEUROSEARCH A/S (DK) | 2005-08-11 | — | — | US | disclosed |
| EP-1513839-A1 | 3-SUBSTITUTED QUINUCLIDINES AND THEIR USE | NEUROSEARCH A/S (DK) | 2005-03-16 | — | — | EP | disclosed |
| WO-2003101987-A1 | 3-SUBSTITUTED QUINUCLIDINES AND THEIR USE | NEUROSEARCH A/S (DK) | 2003-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176756-A1 | 3-Substituted quinuclidines and their use | CHRNA3, CHRNA5, CHRNA6 | NOS1 607/4885CHRM2 20/4885CHRM4 19/4885 |
| US-20080132704-A1 | 3-Substituted quinuclidines and their use | CHRNA3, CHRNA5, CHRM3 | NOS1 731/4885CHRM2 20/4885CHRM4 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.